ArticleThe Lancet. Haematology2025

Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study.

Paolo Strati et al.PubMed ↗Publisher ↗

No numbers read from the abstract.